Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis
PLOS One · 2025
DOI: 10.1371/journal.pone.0335642 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Jingyu Dai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Quality of Life, Cholangitis, Sclerosing, Biomarkers. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre.
Abstract (Originalsprache)
Background & aims Primary sclerosing cholangitis (PSC) is a rare chronic liver disease that impact quality of life (QoL). This study investigated the association between biomarkers of PSC disease severity and QoL.
Methods
Prospective study involving 80 participants with PSC at baseline and 55 at 1-year follow-up. QoL was assessed using patient reported outcomes (PROMs): RAND-SF36, SF6D and PSC-PRO. MRI-MRCP data was analysed using LiverMultiscan for iron-corrected liver T1 (cT1) and MRCP+ for the relative severity of intrahepatic biliary dilatations (RSIBD). Disease severity was also classified using FibroScan liver stiffness (LS), enhanced liver fibrosis (ELF), Mayo risk score (MRS), Amsterdam-Oxford model (AOM), alkaline phosphatase (ALP), presence of extrahepatic disease and dominant stricture (DS). Descriptive and regression analyses were conducted.
Results
At baseline, more advanced PSC was associated with differences in PROMs, AOM > 2, (PSC-PRO PSC symptoms, 5.181, p = 0.048), LS > 9.6 kPa (SF-6D, −0.081, p = 0.027), cT1 > 825ms (SF6D QoL, −0.161, p = 0.004; SF36 PCS, −10.595, p = 0.001; SF36 MCS, −10.726, p = 0.012), DS (PSC-PRO symptoms scores, 5.800, p = 0.025), RSIBD (SF-6D, −0.081, p = 0.016). During follow-up, increase in LS was associated with a reduction in QoL measured via SF-6D (−0.002, p < 0.001), SF36 physical component summary (−0.246, p < 0.001) and SF36 mental component summary (−0.171, p < 0.001).
Conclusions
QoL in PSC was associated with biomarkers of parenchymal liver fibrosis (LS, cT1), biliary disease (dominant strictures, RSIBD), and composite scores of disease severity (AOM). Increasing LS predicted further declines in QoL. Further research should explore MRCP+ metrics and their impact on QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
- Oxford National Institute for Health and Care Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
- Oxford Health National Institute for Health and Care Research (NIHR) Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
- South Warwickshire University Hospital NHS Foundation Trust, Warwick, United Kingdom.
- Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, United Kingdom.
- Perspectum Ltd, Oxford, United Kingdom.
ORCID-Profile: Michael Pavlides, Jose Leal
Förderung
- NIHR Oxford Biomedical Research Centre
Zitieren
APA
Dai, J., Selvaraj, E., Culver, E. L., Bailey, A., Brady, M., Pavlides, M., & Leal, J. (2025). Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis. PLOS One. https://doi.org/10.1371/journal.pone.0335642
Vancouver
Dai J, Selvaraj E, Culver EL, Bailey A, Brady M, Pavlides M, et al. Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis. PLOS One. 2025. doi:10.1371/journal.pone.0335642
BibTeX
@article{Dai2025,
author = {Dai, Jingyu and Selvaraj, Emmanuel and Culver, Emma L and Bailey, Adam and Brady, Michael and Pavlides, Michael and Leal, Jose},
title = {Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0335642}
}
EUVIMED